Health
Anvisa bans sales of irregular medicines in Brazil
The bans cover insulin distributed without authorization, an improperly compounded product and unregistered peptides, as well as two medicine batches with quality issues.
Follow global economy, business, finance, energy, climate and public affairs through original sources, sourced data and context.
The bans cover insulin distributed without authorization, an improperly compounded product and unregistered peptides, as well as two medicine batches with quality issues.